Open AccessTo Study Clinicopathological and Immunohistochemical Expression of Estrogen Receptor, Progesterone Receptor and Her-2/Neu in Prostate Carcinoma
Author(s) -
Manpreet Kaur,
Menka Khanna,
Harjot Kaur,
Rajeev Gupta
Publication year - 2021
Publication title -
annals of pathology and laboratory medicine
Language(s) - English
Resource type - Journals
eISSN - 2394-6466
pISSN - 2349-6983
DOI - 10.21276/apalm.3001
Subject(s) - medicine , immunohistochemistry , stromal cell , prostate , estrogen receptor , progesterone receptor , prostate cancer , her2/neu , carcinoma , pca3 , estrogen , pathology , gynecology , urology , oncology , cancer , breast cancer
Background: Prostate carcinoma is leading cause of cancer related deaths amongst men. This study evaluated expression of ER, PR, HER-2/neu in Prostatic carcinoma and its correlation with Gleason score and other clinical parameters.
Methods: 50 histopathologically proven PCa cases were subjected to IHC for ER, PR, HER-2/neu.
Result: Most common age group involved was 61-80years. Retention of urine was most frequent complaint. Most prominent Gleason score was (3+4) and group grade was 2. ER expression in tumor epithelial cells was 24% and in stromal cells was 36%. PR expression in stromal cells was 32%. HER-2/neu Cytoplasmic positivity was seen in 6% cases. It was seen that with increase in Gleason grade, ER, PR, HER-2/neu positivity was decreased.
Conclusion: ER, PR, HER-2/neu can be used as biomarkers in PCa management.